Exhibit 99.1
Cerecor Reports Third Quarter 2019 Results
-Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 Million
-First Patient Enrolled in Diabetic OH Trial with CERC-301
-Completed Phase 1 Healthy Volunteer Study with CERC-802
-CERC-802 IND Accepted by FDA and Received Fast Track Designation
Rockville, MD, November 14, 2019 — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today its financial results for the third quarter ended September 30, 2019 and provided additional corporate highlights.
“It’s been a transformational start to the back-half of the year for Cerecor. We continue to execute on our plan to increase shareholder value by advancing our clinical pipeline and executing transformative business development deals. CERC-802 achieved several regulatory milestones and had encouraging results from its Phase I Safety Study in Healthy Volunteers. CERC-301 final results were reported from its neurogenic Orthostatic Hypotension (nOH) trial in patients with Parkinson’s disease and is preparing to advance into a proof-of-concept trial investigating its use in Orthostatic Hypotension (OH) associated with Diabetes. Diabetic OH is a significantly larger patient population (15-fold greater than nOH with ~3 million U.S. patients) ; and there are no approved therapies. Additionally, the sale of the Pediatric Portfolio strengthens our balance sheet by providing non-dilutive capital for R&D helping us to advance CERC-801 towards NDA approval, allowing us to obtain a PRV for potential monetization.,” said Dr. Simon Pedder, Executive Chairman of the Board.
Corporate Update
• | On October 10, 2019, the Company entered into, and subsequently closed on, an asset purchase agreement with Aytu BioScience, Inc. (Aytu) to sell its Pediatric Portfolio with the overall deal valued in excess of $43 million |
◦ | The Pediatric Portfolio includes the following five product lines: Aciphex® Sprinkle™, Cefaclor for Oral Suspension, Karbinal® ER, Flexichamber™, Poly-Vi-Flor® and Tri-Vi-Flor™ |
◦ | Composite of $17 million in cash and preferred stock ($4.5 in cash & 12.5 million of Aytu stock) |
◦ | Assumption of Cerecor’s outstanding payment obligations payable to Deerfield CSF, LLC (“Deerfield Note”) and other liabilities in excess of $15 million |
◦ | Elimination of existing royalty obligations & various commercial accruals of $11 million |
◦ | Estimated annual expense reduction of $7 to $9 million associated with Commercial Sales organization transfer to Aytu |
◦ | The Company retained all rights to Millipred®, which is the Company’s most profitable product. Millipred® profits will assist the Company in funding its pipeline assets and may provide future optionality towards monetization and further pipeline funding |
• | James Harrell, EVP of Marketing and Investor Relations, was promoted to Chief Commercial Officer |
• | Private Placement of ~$3.7 million from Armistice Capital in September 2019 |
Research and Development Update
Orphan Pipeline
1
• | The CDG FIRST trial enrolled its first patient in July 2019. The purpose of the trial is to investigate the natural course of disease and current treatment approaches for Congenital Disorders of Glycosylation (CDGs). The data acquired through the CDG FIRST study is expected to be used to support regulatory filings for the CERC-800s series (CERC-801, CERC-802 and CERC-803), and may help to expedite the first approved treatment(s) for CDGs |
• | The U.S. Food and Drug Administration (“FDA”) communicated that the Company may proceed under the IND for CERC-802 in MPI-CDG (Mannose-Phosphate Isomerase) |
• | CERC-802 obtained fast-track designation (FTD) from the FDA. Both CERC-801 and CERC-802 now have fast-track designation from the FDA |
• | CERC-802 completed its Phase I Safety Study in healthy volunteers. The single-center, US-based safety, tolerability and pharmacokinetic study was an open-label, randomized, single-dose, 4-way crossover study in 16 healthy adult volunteers. Pharmacokinetic (PK) data is expected in early 2020 |
Neurological Pipeline
• | CERC-301 completed and reported its final results from its Phase I trial in nOH |
◦ | The 20mg dose group (the highest dose tested) demonstrated rapid, robust and sustained increases in blood pressure over baseline and placebo with a maximum improvement of 29.1 mmHg throughout the study |
◦ | Additionally, there was strong dose-related consistency of plasma concentrations across all doses studied. We believe this data may support a single daily dose and has the potential to be used in a broader Orthostatic Hypotension patient population |
• | Initiated a Phase I Proof-of-Concept trial in diabetic orthostatic hypotension (DOH) |
◦ | The purpose of this study is to assess the single dose effects of CERC-301 in patients with symptomatic DOH |
◦ | This study is a randomized, double-blind, placebo-controlled, two-way cross-over trial over two 24-hour in-clinic visits. At each visit, subjects will receive a single 20 mg dose of CERC-301 or placebo then undergo a series of orthostatic challenge tests over the 24 hour in-clinic period |
◦ | Patients will also complete an OH symptomatic assessment following each orthostatic challenge. Safety, tolerability, PK data will also be collected. As part of the routine laboratory tests, particular interest will be paid to the patient’s plasma glucose levels over the course of the study |
Third Quarter 2019 Financial Results
Net product revenue increased $1.4 million to $5.5 million for the three months ended September 30, 2019 as compared to the same period in 2018. The increase was due to improved product mix and higher sales volume during the current period.
Total operating expenses were $9.3 million for the three months ended September 30, 2019, compared to operating expenses of $28.4 million for the three months ended September 30, 2018. The significant decrease was due to $18.7 million of in-process research and development costs as a result of the Ichorion acquisition in 2018.
Net loss for the three months ended September 30, 2019 was $4.0 million compared to net loss of $24.6 million for the three months ended September 30, 2018. The significant decrease was largely a result of the 2018 in-process research and development costs highlighted above.
The cash balance was $5.3 million for the quarter ended September 30, 2019. The company received $4.5 million in cash from Aytu from the sale of the pediatric portfolio in the fourth quarter of 2019.
2
Unaudited Condensed Consolidated Statements of Operations
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2019 (a), (b) | 2018 (a) | 2019 (a), (b) | 2018 (a) | |||||||||||||
(in thousands, except per share data) | (in thousands, except per share data) | |||||||||||||||
Revenues: | ||||||||||||||||
Product revenue, net | $ | 5,513 | $ | 4,075 | $ | 15,374 | $ | 13,046 | ||||||||
License and other revenue | 100 | — | 100 | — | ||||||||||||
Sales force revenue | — | — | — | 297 | ||||||||||||
Total revenues, net | 5,613 | 4,075 | 15,474 | 13,343 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of product sales | 1,435 | 3,111 | 3,241 | 5,398 | ||||||||||||
Research and development | 1,743 | 1,048 | 8,857 | 3,780 | ||||||||||||
Acquired in-process research and development | — | 18,724 | — | 18,724 | ||||||||||||
General and administrative | 2,679 | 1,884 | 7,779 | 7,834 | ||||||||||||
Sales and marketing | 2,631 | 2,311 | 8,676 | 5,889 | ||||||||||||
Amortization expense | 1,037 | 1,065 | 3,195 | 3,316 | ||||||||||||
Impairment of intangible assets | — | 160 | 1,449 | 1,861 | ||||||||||||
Change in fair value of contingent consideration | (197 | ) | 85 | (1,009 | ) | 361 | ||||||||||
Total operating expenses | 9,328 | 28,388 | 32,188 | 47,163 | ||||||||||||
Loss from operations | (3,715 | ) | (24,313 | ) | (16,714 | ) | (33,820 | ) | ||||||||
Other (expense) income: | ||||||||||||||||
Change in fair value of warrant liability and unit purchase option liability | 35 | (3 | ) | 7 | (23 | ) | ||||||||||
Other (expense) income, net | (15 | ) | — | (24 | ) | 19 | ||||||||||
Interest expense, net | (206 | ) | (235 | ) | (614 | ) | (578 | ) | ||||||||
Total other expense, net | (186 | ) | (238 | ) | (631 | ) | (582 | ) | ||||||||
Net loss before taxes | (3,901 | ) | (24,551 | ) | (17,345 | ) | (34,402 | ) | ||||||||
Income tax expense | 115 | 52 | 349 | 92 | ||||||||||||
Net loss | $ | (4,016 | ) | $ | (24,603 | ) | $ | (17,694 | ) | $ | (34,494 | ) | ||||
Net loss per share of common stock, basic and diluted | $ | (0.07 | ) | $ | (0.71 | ) | $ | (0.31 | ) | $ | (1.05 | ) | ||||
Net loss per share of preferred stock, basic and diluted | $ | (0.35 | ) | $ | — | $ | (1.56 | ) | $ | — | ||||||
(a) The unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2019 and 2018 have been derived from the reviewed financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. | ||||||||||||||||
(b) The unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2019 do not include the impact of the Aytu transaction because the transaction was entered into and subsequently closed in the fourth quarter of 2019. | ||||||||||||||||
Condensed Consolidated Balance Sheets
3
September 30, 2019 (a), (b) | December 31, 2018 (a) | |||||||
(unaudited) | ||||||||
Assets | (in thousands) | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 5,251 | $ | 10,646 | ||||
Accounts receivable, net | 4,956 | 3,158 | ||||||
Other receivables | 208 | 5,469 | ||||||
Inventory, net | 402 | 1,111 | ||||||
Prepaid expenses and other current assets | 1,670 | 1,529 | ||||||
Restricted cash, current portion | 102 | 19 | ||||||
Total current assets | 12,589 | 21,932 | ||||||
Property and equipment, net | 1,497 | 587 | ||||||
Intangible assets, net | 26,595 | 31,239 | ||||||
Goodwill | 16,411 | 16,411 | ||||||
Restricted cash, net of current portion | 102 | 82 | ||||||
Total assets | $ | 57,194 | $ | 70,251 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 826 | $ | 1,446 | ||||
Accrued expenses and other current liabilities | 13,134 | 19,731 | ||||||
Income taxes payable | 1,015 | 2,032 | ||||||
Long-term debt, current portion | 1,050 | 1,050 | ||||||
Contingent consideration, current portion | 1,237 | 1,957 | ||||||
Total current liabilities | 17,262 | 26,216 | ||||||
Long-term debt, net of current portion | 14,255 | 14,328 | ||||||
Contingent consideration, net of current portion | 6,236 | 7,094 | ||||||
Deferred tax liability, net | 98 | 69 | ||||||
License obligations | — | 1,250 | ||||||
Other long-term liabilities | 1,122 | 386 | ||||||
Total liabilities | 38,973 | 49,343 | ||||||
Stockholders’ equity: | ||||||||
Common stock—$0.001 par value; 200,000,000 shares authorized at September 30, 2019 and December 31, 2018; 44,106,794 and 40,804,189 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively | 44 | 41 | ||||||
Preferred stock—$0.001 par value; 5,000,000 shares authorized at September 30, 2019 and December 31, 2018; 2,857,143 shares issued and outstanding at September 30, 2019 and December 31, 2018 | 3 | 3 | ||||||
Additional paid-in capital | 134,086 | 119,082 | ||||||
Accumulated deficit | (115,912 | ) | (98,218 | ) | ||||
Total stockholders’ equity | 18,221 | 20,908 | ||||||
Total liabilities and stockholders’ equity | $ | 57,194 | $ | 70,251 | ||||
(a) The condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018 have been derived from the reviewed and audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. | ||||||||
(b) The condensed consolidated balance sheet as of September 30, 2019 do not include the impact of the Aytu transaction because the transaction was entered into and subsequently closed in the fourth quarter of 2019. | ||||||||
4
Outlook
Cerecor was on track to achieve its 2019 revenue guidance in a range of $20 to $22 million. However, as a result of the sale of the pediatric portfolio to Aytu, Cerecor will no longer be providing revenue guidance.
About Cerecor
Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurological conditions. The Company is building a robust pipeline of innovative therapies in orphan diseases and neurology. The Company’s pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (“CERC-800 programs”), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation. The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation (“ODD”) to all three CERC-800 compounds, thus qualifying the Company to receive a Priority Review Voucher (“PRV”) upon approval of a new drug application (“NDA”). The PRV may be sold or transferred an unlimited number of times. The Company plans to leverage the 505(b)(2) NDA pathway for all three compounds to accelerate development and approval. The Company is also developing one other preclinical pediatric orphan rare disease compound, CERC-913, for the treatment of mitochondrial DNA Depletion Syndrome. The Company’s neurology pipeline is led by CERC-301, a Glutamate NR2B selective, NMDA Receptor antagonist, which Cerecor is currently exploring as a novel treatment for orthostatic hypotension. The Company is also developing CERC-406, a CNS-targeted COMT inhibitor for Parkinson’s Disease. The Company also has one marketed product, Millipred®, an oral prednisolone indicated across a wide variety of inflammatory conditions and indications.
For more information about Cerecor, please visit www.cerecor.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; the expansion of Cerecor’s drug portfolio; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials; regulatory risks; reliance on and the need to attract, integrate and retain key personnel; Cerecor’s cash position and the potential need for it to raise additional capital; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For Media and Investor Inquiries
James Harrell,
Chief Commercial Officer
Cerecor Inc.
jharrell@cerecor.com
623.439.2220 office
5